Secondary endpoint results for cognitive and functional measurements (CDR-SB)
SECONDARY
No significant difference in the CDR-SB score (a secondary endpoint) was observed between the gosuranemab groups and the placebo group. The difference between the treated groups and the placebo group at week 78 was –0.01 (